{
  "documentMetadata": {
    "title": "Pyomyositis",
    "lastUpdated": "2025-01-27",
    "sourceFile": "Pyomyositis.pdf"
  },
  "content": [
    {
      "type": "header",
      "level": 1,
      "text": "Clinical Setting"
    },
    {
      "type": "list",
      "items": [
        "Can complicate Staph. aureus bacteremia.",
        "Common in the tropics; rare in temperate zones.",
        "Injections and injection drug use are risk factors",
        "May follow exercise or muscle injury."
      ]
    },
    {
      "type": "header",
      "level": 1,
      "text": "Etiologies"
    },
    {
      "type": "list",
      "items": [
        "Staph. aureus",
        "Streptococcus sp. (Group A and others)",
        "Gram-negative bacilli (rare)",
        "Anaerobic bacteria (rarely Clostridium species)"
      ]
    },
    {
      "type": "header",
      "level": 1,
      "text": "Primary Regimens"
    },
    {
      "type": "list",
      "items": [
        "If suspected or proven MSSA: (Nafcillin or Oxacillin) 2 gm IV q4h or Cefazolin 2 gm IV q8h",
        "If suspected or proven MRSA: Vancomycin 15-20 mg/kg IV q8-12h to achieve preferred target AUC24 400-600 µg/mL x hr (see vancomycin AUC dosing calculator; alternative is trough of 15-20 µg/mL)",
        "If anaerobes suspected/proven, add Metronidazole"
      ]
    },
    {
      "type": "header",
      "level": 1,
      "text": "Alternative Regimens"
    },
    {
      "type": "list",
      "items": [
        "Linezolid or Daptomcyin are alternatives to vancomycin for MRSA infection.",
        "Add gram-negative coverage (to Staph/Strep coverage) in immunocompromised patients."
      ]
    },
    {
      "type": "header",
      "level": 1,
      "text": "Antimicrobial Stewardship"
    },
    {
      "type": "list",
      "items": [
        "Surgical or CT-guided drainage recommended in all cases",
        "Duration of therapy is 2-4 weeks, depending on clinical response, with at least 4 weeks recommended for those with S. aureus bacteremia",
        "Can transition to pathogen-directed oral therapy to complete therapy once the patient has responded."
      ]
    },
    {
      "type": "header",
      "level": 1,
      "text": "Comments"
    },
    {
      "type": "list",
      "items": [
        "Practice Guideline: Clin Infect Dis 59:147, 2014."
      ]
    }
  ]
}